Single-Dose MM120 (LSD) Demonstrates Sustained Anxiety Relief in Phase 2b GAD Trial
核心洞察
A phase 2b trial of 198 adults with generalized anxiety disorder (搜索) found that a single 100 μg dose of MM120 (LSD) significantly reduced symptoms with effects lasting up to 12 weeks.
The study demonstrated a clear dose-response relationship, with 100 μg emerging as the optimal dose, achieving 65% response rate and 48% remission rate at week 4.
MM120 was well tolerated with only transient perceptual changes and mild adverse events, supporting its advancement to phase 3 development.
A single dose of MM120 (lysergide D-tartrate, LSD) has demonstrated significant and sustained reduction in generalized anxiety disorder (搜索) (GAD (搜索)) symptoms in a phase 2b randomized trial, with therapeutic benefits lasting up to 12 weeks. The study, published in JAMA, represents a major advancement in psychedelic medicine for anxiety disorders.
Phase 2b Trial Results Show Optimal Dosing
The randomized trial enrolled 198 adults with moderate to severe GAD (搜索) and evaluated multiple doses of MM120 to establish optimal therapeutic levels. The study demonstrated a clear dose-response relationship, with the 100 μg dose emerging as the most effective treatment option.
At week 4, participants who received the 100 μg dose achieved remarkable clinical outcomes, with 65% experiencing a therapeutic response and 48% achieving remission. These improvements were maintained through the 12-week follow-up period, demonstrating the durability of the single-dose treatment approach.
Safety Profile and Tolerability
MM120 demonstrated a favorable safety profile throughout the trial period. Patients experienced only transient perceptual changes and mild adverse events, with no serious safety concerns reported. The tolerability profile supports the drug's potential for broader clinical application in GAD (搜索) treatment.
The sustained therapeutic effects observed in the trial contrast sharply with traditional anxiety medications that require daily dosing and often produce tolerance over time. The single-dose approach could represent a paradigm shift in how anxiety disorders are treated.
Clinical Significance for GAD Treatment
Generalized anxiety disorder (搜索) affects millions of patients worldwide, and current treatment options often require continuous daily medication with variable efficacy. The MM120 results suggest that a single therapeutic session could provide months of symptom relief, potentially transforming the treatment landscape for GAD (搜索).
The rapid onset of therapeutic effects, combined with the sustained duration of benefit, addresses key limitations of existing GAD (搜索) treatments. Traditional anxiolytics and antidepressants typically require weeks to months to achieve full therapeutic effect and must be taken continuously to maintain benefits.
Advancing to Phase 3 Development
Based on these positive phase 2b results, MM120 is advancing to phase 3 clinical development. The clear demonstration of dose-response relationship and the identification of 100 μg as the optimal dose provides a strong foundation for larger-scale efficacy trials.
The findings support the growing body of evidence for psychedelic-assisted therapies in mental health treatment. Unlike traditional psychedelics that may produce significant hallucinogenic effects, MM120's profile appears optimized for therapeutic benefit while maintaining tolerability.